logo-loader
viewNetscientific PLC

NetScientific portfolio company ProAxsis receives grant by Invest North Ireland

The healthcare IP commercialisation group said the project will assist in the clinical validation of new therapeutics for deubiquitinases (DUBs) as part of a £150,000 project

man looking at microscope
NetScientific holds 54% of ProAxsis on a fully-diluted basis

NetScientific PLC (LON:NSCI) has announced its portfolio company ProAxsis  has been awarded a grant by Invest North Ireland to support the development of its proprietary ProteaseTag technology to identify and quantify active protease biomarkers.

The healthcare IP commercialisation group said the project will assist in the clinical validation of new therapeutics for deubiquitinases (DUBs) as part of a £150,000 project.

READ: NetScientific says latest data shows “invaluable potential” of portfolio company Wanda’s technology

The company said DUBs are thought to play significant roles in the pathogenesis of several types of cancer as well as neurodegenerative disorders, and as such are of high interest to the pharmaceutical industry.

NetScientific holds 54% of ProAxsis on a fully-diluted basis.

Francois R. Martelet, chief executive officer of NetScientific and chairman of ProAxsis, said: "The expansion of ProteaseTag technology from serine into cysteine proteases represents a strategic cornerstone for ProAxsis and substantially enlarges the addressable market down the line.”

He added: ”We thank Invest NI and congratulate ProAxsis on its continuing momentum towards becoming the leader in assays for active protease biomarker measurement."

Quick facts: Netscientific PLC

Price: 3.5 GBX

AIM:NSCI
Market: AIM
Market Cap: £2.75 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Netscientific PLC named herein, including the promotion by the Company of Netscientific PLC in any Content on the Site, the Company receives...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Netscientific PLC raises £5mln to speed up portfolio commercialisation

Francois Martelet, chief executive of Netscientific PLC (LON:NSCI), caught up with Proactive's Andrew Scott following the close of their £5mln fundraise. Netscientific has a core portfolio of five companies and will use the additional funding to accelerate either the float or sale of one...

on 12/4/18

2 min read